PSMD1

Across TCGA pan-cancer cohorts, PSMD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMD1 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PSMD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMD1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and OV are the cancer types where PSMD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.698	0.967	<.001	61	view →
LUAD	OS	Median	All	0.580	0.880	<.001	33	view →
OV	DFS	Quartile	All	0.465	0.884	.033	8	view →
HNSC	DFS	Median	II,III,IV	0.865	0.697	.031	3	view →
CCRCC	OS	Quartile	III,IV	0.513	0.912	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMD1–PDAC (OS)

Open the PDAC breakdown →